Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
Cannabis Industry
Cannabis Companies Demonstrate the Diverse Nature of the Global Marijuana Market
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
How InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Breakthrough Biosynthesis Works - Video
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
For ChineseInvestors.com, Inc. (CIIX) Beauty is more than Just Skin Deep
ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line of hemp-infused skin care products in China. The cannabinoid content of the line makes these products more than just cosmetics.
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Technology Targets Many Massive Markets
The innovative biotech has developed a lipid-based system that delivers bioactive compounds more efficiently.
Singlepoint, Inc. (SING) Interview Reveals How the Cannabis Industry is Incorporating Technology
Singlepoint, Inc. (OTC: SING), a publicly traded holding company, offers payment solutions to the cannabis industry through its SingleSeed subsidiary.
CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017
CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
Singlepoint, Inc. (SING) CEO Greg Lambrecht Reveals High Points of Convectium Acquisition
There should be “more funding on the way,” according to Singlepoint CEO Greg Lambrecht, who discussed the acquisition in a recent episode of MoneyTV with Donald Baillargeon.
SinglePoint, Inc.’s (SING) Unique Strategy Aims to Remove Risk While Expanding Portfolio
SinglePoint (OTC: SING) continues to pursue strategic opportunities to widen its foothold in the cannabis industry while hedging itself against potential risks regarding the legality of marijuana.
At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles
Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology
If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind.
This Company Figured Out How to Make CBD from E. Coli
InMed Pharmaceuticals is making bacteria-bred cannabinoids “identical to those found in nature,” sans chemicals or even cannabis.
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development
The future of cannabinoid-based medicine hinges on such innovations which is: the ability to produce cannabinoids identical to those found in nature in a safe, consistent and economical fashion to advance cannabis-based drug development.
DOJA Cannabis Company Provides Production Update
DOJA Cannabis Company Limited (CSE: DOJA) is pleased to announce that we commenced cultivating our first cannabis strains in July and that the plants have taken well to their new home at DOJA's production facility in British Columbia's Okanagan Valley.